430 related articles for article (PubMed ID: 17332365)
1. Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells.
Zeng Y; Huebener N; Fest S; Weixler S; Schroeder U; Gaedicke G; Xiang R; Schramm A; Eggert A; Reisfeld RA; Lode HN
Cancer Res; 2007 Mar; 67(5):2331-8. PubMed ID: 17332365
[TBL] [Abstract][Full Text] [Related]
2. Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2.
Zeng Y; Jiang J; Huebener N; Wenkel J; Gaedicke G; Xiang R; Lode HN
Cancer Lett; 2005 Oct; 228(1-2):187-93. PubMed ID: 15953676
[TBL] [Abstract][Full Text] [Related]
3. Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumors.
Nukiwa M; Andarini S; Zaini J; Xin H; Kanehira M; Suzuki T; Fukuhara T; Mizuguchi H; Hayakawa T; Saijo Y; Nukiwa T; Kikuchi T
Eur J Immunol; 2006 Apr; 36(4):1019-27. PubMed ID: 16525992
[TBL] [Abstract][Full Text] [Related]
4. Antitumor immune response by CX3CL1 fractalkine gene transfer depends on both NK and T cells.
Xin H; Kikuchi T; Andarini S; Ohkouchi S; Suzuki T; Nukiwa T; Huqun ; Hagiwara K; Honjo T; Saijo Y
Eur J Immunol; 2005 May; 35(5):1371-80. PubMed ID: 15789339
[TBL] [Abstract][Full Text] [Related]
5. Involvement of interaction between Fractalkine and CX3CR1 in cytotoxicity of natural killer cells against tumor cells.
Zhang X; Wei H; Wang H; Tian Z
Oncol Rep; 2006 Feb; 15(2):485-8. PubMed ID: 16391873
[TBL] [Abstract][Full Text] [Related]
6. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
[TBL] [Abstract][Full Text] [Related]
7. Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses.
Fraticelli P; Sironi M; Bianchi G; D'Ambrosio D; Albanesi C; Stoppacciaro A; Chieppa M; Allavena P; Ruco L; Girolomoni G; Sinigaglia F; Vecchi A; Mantovani A
J Clin Invest; 2001 May; 107(9):1173-81. PubMed ID: 11342581
[TBL] [Abstract][Full Text] [Related]
8. Activation of human natural killer cells by recombinant membrane-expressed fractalkine on the surface of tumor cells.
Zhang X; Wei H; Chen Q; Tian Z
Oncol Rep; 2007 Jun; 17(6):1371-5. PubMed ID: 17487393
[TBL] [Abstract][Full Text] [Related]
9. T cell costimulation by fractalkine-expressing synoviocytes in rheumatoid arthritis.
Sawai H; Park YW; Roberson J; Imai T; Goronzy JJ; Weyand CM
Arthritis Rheum; 2005 May; 52(5):1392-401. PubMed ID: 15880821
[TBL] [Abstract][Full Text] [Related]
10. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
[TBL] [Abstract][Full Text] [Related]
11. Expression of fractalkine and its receptor, CX3CR1, in atopic dermatitis: possible contribution to skin inflammation.
Echigo T; Hasegawa M; Shimada Y; Takehara K; Sato S
J Allergy Clin Immunol; 2004 May; 113(5):940-8. PubMed ID: 15131578
[TBL] [Abstract][Full Text] [Related]
12. Fractalkine mediates natural killer-dependent antitumor responses in vivo.
Lavergne E; Combadière B; Bonduelle O; Iga M; Gao JL; Maho M; Boissonnas A; Murphy PM; Debré P; Combadière C
Cancer Res; 2003 Nov; 63(21):7468-74. PubMed ID: 14612547
[TBL] [Abstract][Full Text] [Related]
13. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
14. Adenovirus-mediated interleukin-18 mutant in vivo gene transfer inhibits tumor growth through the induction of T cell immunity and activation of natural killer cell cytotoxicity.
Hwang KS; Cho WK; Yoo J; Seong YR; Kim BK; Kim S; Im DS
Cancer Gene Ther; 2004 Jun; 11(6):397-407. PubMed ID: 15044962
[TBL] [Abstract][Full Text] [Related]
15. Progression of natural immunity during one-year treatment of residual disease in neuroblastoma patients with high doses of interleukin-2 after autologous bone marrow transplantation.
Martí F; Pardo N; Peiró M; Bertran E; Amill B; García J; Cubells J; Rueda F
Exp Hematol; 1995 Dec; 23(14):1445-52. PubMed ID: 8542930
[TBL] [Abstract][Full Text] [Related]
16. Fractalkine in vascular biology: from basic research to clinical disease.
Umehara H; Bloom ET; Okazaki T; Nagano Y; Yoshie O; Imai T
Arterioscler Thromb Vasc Biol; 2004 Jan; 24(1):34-40. PubMed ID: 12969992
[TBL] [Abstract][Full Text] [Related]
17. Anti-neuroblastoma effect of ch14.18 antibody produced in CHO cells is mediated by NK-cells in mice.
Zeng Y; Fest S; Kunert R; Katinger H; Pistoia V; Michon J; Lewis G; Ladenstein R; Lode HN
Mol Immunol; 2005 Jul; 42(11):1311-9. PubMed ID: 15950727
[TBL] [Abstract][Full Text] [Related]
18. Characterization and tumorigenicity of human neuroblastoma cells transfected with the IL-2 gene.
Corrias MV; Basso S; Meazza R; Musiani P; Santi L; Bocca P; Occhino M; Ferrini S; Pistoia V
Cancer Gene Ther; 1998; 5(1):38-44. PubMed ID: 9476965
[TBL] [Abstract][Full Text] [Related]
19. Membrane-bound form of fractalkine induces IFN-gamma production by NK cells.
Yoneda O; Imai T; Nishimura M; Miyaji M; Mimori T; Okazaki T; Domae N; Fujimoto H; Minami Y; Kono T; Bloom ET; Umehara H
Eur J Immunol; 2003 Jan; 33(1):53-8. PubMed ID: 12594832
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma.
Shimizu T; Berhanu A; Redlinger RE; Watkins S; Lotze MT; Barksdale EM
J Pediatr Surg; 2001 Aug; 36(8):1285-92. PubMed ID: 11479878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
